E-LIB Suche - Ergebnisse für: Schatz, U.

1

High interindividual variability in LDL-cholesterol reducti..:

Makhmudova, U. ; Schatz, U. ; Perakakis, N....
Clinical Research in Cardiology. 112 (2023) 11 - p. 1639-1649 , 2023

Link: https://doi.org/10.1007/..

2

High individual variability in LDL-reductions after inclisi..:

Makhmudova, U ; Schatz, U ; Kassner, U...
European Heart Journal. 43 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

3

P.159Disease spectrum in nemaline myopathy due to LMOD3 mil..:

Weiss, S. ; Schatz, U. ; Zschoke, J....
Neuromuscular Disorders. 29 (2019) - p. S94-S95 , 2019

Link: https://doi.org/10.1016/..

4

Lipoprotein(a)—an interdisciplinary challenge:

Julius, U. ; Tselmin, S. ; Schatz, U...
Clinical Research in Cardiology Supplements. 14 (2019) S1 - p. 20-27 , 2019

Link: https://doi.org/10.1007/..

5

Lipoprotein(a) and proprotein convertase subtilisin/kexin t..:

Julius, U. ; Tselmin, S. ; Schatz, U...
Clinical Research in Cardiology Supplements. 14 (2019) S1 - p. 45-50 , 2019

Link: https://doi.org/10.1007/..

6

Kinetics of Lipoprotein(a) in patients undergoing weekly li..:

Tselmin, S. ; Müller, G. ; Schatz, U....
Atherosclerosis Supplements. 30 (2017) - p. 209-216 , 2017

Link: https://doi.org/10.1016/..

7

Lipoprotein apheresis influences monocyte subpopulations:

Jellinghaus, S. ; Reich, C. ; Schatz, U....
Atherosclerosis Supplements. 30 (2017) - p. 108-114 , 2017

Link: https://doi.org/10.1016/..

8

Most significant reduction of cardiovascular events in pati..:

Schatz, U. ; Tselmin, S. ; Müller, G....
Atherosclerosis Supplements. 30 (2017) - p. 246-252 , 2017

Link: https://doi.org/10.1016/..

9

Elevated lipoprotein(a) levels result in a high cardiovascu..:

Schatz, U. ; Fischer, S. ; Julius, U...
Atherosclerosis. 252 (2016) - p. e127-e128 , 2016

Link: https://doi.org/10.1016/..

10

Practical recommendations for the management of hyperlipide..:

Fischer, S. ; Schatz, U. ; Julius, U.
Atherosclerosis Supplements. 18 (2015) - p. 194-198 , 2015

Link: https://doi.org/10.1016/..

11

Adverse events of lipoprotein apheresis and immunoadsorptio..:

Dittrich-Riediger, J. ; Schatz, U. ; Hohenstein, B..
Atherosclerosis Supplements. 18 (2015) - p. 45-52 , 2015

Link: https://doi.org/10.1016/..

12

TIDILAP: Treatment of iron deficiency in lipoprotein aphere..:

Schatz, U. ; Illigens, B.M.W. ; Siepmann, T....
Atherosclerosis Supplements. 18 (2015) - p. 199-208 , 2015

Link: https://doi.org/10.1016/..

13

Effects of different lipoprotein apheresis methods on serum..:

Julius, U. ; Siegert, G. ; Kostka, H...
Atherosclerosis Supplements. 18 (2015) - p. 95-102 , 2015

Link: https://doi.org/10.1016/..

14

Lipoprotein(a) als Arteriosklerose-Risikofaktor:

Fischer, S. ; Julius, U. ; Tselmin, S...
DMW - Deutsche Medizinische Wochenschrift. 139 (2014) 23 - p. 1204-1206 , 2014

Link: https://doi.org/10.1055/..

15

Current standards in diagnosis and therapy of hyperlipoprot..:

Fischer, S. ; Schatz, U. ; Julius, U.
Atherosclerosis Supplements. 14 (2013) 1 - p. 15-18 , 2013

Link: https://doi.org/10.1016/..